Sabina Signoretti Selected Research

cabozantinib

1/2022	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.
9/2021	Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
8/2021	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
10/2019	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
1/2017	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sabina Signoretti Research Topics

Disease

112	Neoplasms (Cancer) 11/2022 - 01/2002
66	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 04/2005
16	Hypoxia (Hypoxemia) 01/2019 - 08/2004
15	Kidney Neoplasms (Kidney Cancer) 01/2022 - 05/2005
14	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 03/2004
12	Carcinogenesis 12/2019 - 06/2002
10	Neoplasm Metastasis (Metastasis) 01/2020 - 02/2011
7	Disease Progression 01/2022 - 01/2007
7	Breast Neoplasms (Breast Cancer) 11/2016 - 09/2002
6	Carcinoma (Carcinomatosis) 01/2020 - 06/2011
6	Adenocarcinoma 03/2015 - 07/2008
4	Melanoma (Melanoma, Malignant) 01/2019 - 08/2004
4	Necrosis 07/2016 - 08/2004
4	Prostatic Intraepithelial Neoplasia 01/2013 - 06/2002
3	Lung Neoplasms (Lung Cancer) 12/2019 - 04/2005
3	Body Weight (Weight, Body) 06/2009 - 07/2006
2	Tics (Tic) 01/2021 - 01/2019
2	Testicular Neoplasms (Testicular Cancer) 01/2016 - 01/2016
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016 - 12/2015

Drug/Important Bio-Agent (IBA)

29	Biomarkers (Surrogate Marker)IBA 11/2022 - 06/2008
17	Proteins (Proteins, Gene)FDA Link 11/2020 - 09/2002
12	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2016 - 01/2007
10	Sunitinib (Sutent)FDA Link 01/2021 - 05/2009
9	Immune Checkpoint InhibitorsIBA 10/2021 - 01/2018
8	Everolimus FDA Link 01/2022 - 05/2014
8	AndrogensIBA 01/2022 - 05/2003
8	Pharmaceutical PreparationsIBA 01/2021 - 05/2005
8	Transcription Factors (Transcription Factor)IBA 01/2019 - 07/2005
8	Carbonic Anhydrase IXIBA 06/2016 - 05/2005
8	Sorafenib (BAY 43-9006)FDA Link 11/2013 - 08/2007
7	B7-H1 AntigenIBA 01/2022 - 02/2015
7	NivolumabIBA 01/2022 - 12/2015
7	Phosphotransferases (Kinase)IBA 01/2017 - 08/2008
6	MTOR InhibitorsIBA 01/2022 - 01/2007
6	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2015
6	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022 - 08/2007
6	Interleukin-2 (IL2)IBA 05/2017 - 05/2005
6	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 11/2012
5	cabozantinibIBA 01/2022 - 01/2017
5	Histone DemethylasesIBA 12/2019 - 08/2011
5	EnzymesIBA 05/2014 - 03/2009
4	Mechanistic Target of Rapamycin Complex 1IBA 01/2022 - 07/2010
4	Bevacizumab (Avastin)FDA Link 01/2020 - 05/2009
4	temsirolimus FDA Link 01/2020 - 09/2007
4	Sirolimus (Rapamycin)FDA Link 07/2019 - 07/2010
4	ParaffinIBA 10/2017 - 08/2004
4	AntibodiesIBA 05/2017 - 06/2015
4	Fatty Acid Synthases (Fatty Acid Synthase)IBA 10/2016 - 03/2004
4	TOR Serine-Threonine KinasesIBA 08/2016 - 01/2007
4	AntigensIBA 01/2016 - 06/2011
4	Protein Isoforms (Isoforms)IBA 03/2015 - 06/2009
3	Biological ProductsIBA 01/2021 - 10/2016
3	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 07/2019 - 06/2010
3	Messenger RNA (mRNA)IBA 10/2016 - 07/2013
3	Cisplatin (Platino)FDA LinkGeneric 05/2016 - 06/2014
3	pazopanib FDA Link 03/2015 - 09/2013
3	Hormones (Hormone)IBA 01/2015 - 06/2006
3	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2014 - 05/2005
3	Phenobarbital (Luminal)FDA Link 12/2012 - 05/2003
3	Cyclin D1IBA 10/2012 - 07/2010
3	Angiogenesis InhibitorsIBA 10/2010 - 08/2007
3	Androgen Receptors (Androgen Receptor)IBA 04/2009 - 12/2004
2	Von Hippel-Lindau Tumor Suppressor ProteinIBA 01/2022 - 12/2017
2	IpilimumabIBA 01/2022 - 01/2021
2	InterferonsIBA 01/2022 - 05/2009
2	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2017
2	Retinoblastoma ProteinIBA 12/2019 - 08/2011
2	dactolisibIBA 07/2019 - 07/2010
2	Histones (Histone)IBA 01/2019 - 08/2011
2	Programmed Cell Death 1 ReceptorIBA 01/2019 - 02/2018
2	LipidsIBA 01/2019 - 01/2018
2	LigandsIBA 01/2018 - 12/2016
2	Formaldehyde (Formol)FDA Link 10/2017 - 08/2004
2	aldesleukin (Proleukin)FDA Link 05/2017 - 02/2015
2	UbiquitinIBA 11/2016 - 09/2002
2	Ligases (Synthetase)IBA 11/2016 - 09/2002
2	Fatty Acids (Saturated Fatty Acids)IBA 10/2016 - 06/2009
2	Fumarate Hydratase (Fumarase)IBA 01/2016 - 03/2009
2	MicroRNAs (MicroRNA)IBA 01/2016 - 07/2013
2	N 30IBA 01/2016 - 04/2010
2	Oxygen (Dioxygen)IBA 01/2016 - 09/2010
2	Oncogene Proteins (Oncogene Protein)IBA 08/2014 - 08/2011
2	Lactate Dehydrogenase 5IBA 05/2014 - 03/2009
2	Lactic Acid (Lactate)FDA LinkGeneric 05/2014 - 03/2009
2	Pyruvic Acid (Pyruvate)IBA 05/2014 - 03/2009
2	AgarIBA 12/2013 - 04/2009
2	Phosphatidylinositols (Phosphatidylinositol)IBA 11/2013 - 07/2005
2	CytokinesIBA 12/2012 - 12/2011
2	Cyclin-Dependent Kinase Inhibitor p16IBA 11/2012 - 01/2002
2	Prostate-Specific Antigen (Semenogelase)IBA 02/2011 - 06/2006
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2010 - 06/2009
2	TensinsIBA 06/2010 - 09/2007

Therapy/Procedure

57	Therapeutics 01/2022 - 09/2002
8	Immunotherapy 11/2022 - 01/2016
6	Radiofrequency Ablation 12/2010 - 04/2005
4	Castration 01/2022 - 06/2006
3	Precision Medicine 10/2018 - 06/2008
3	Drug Therapy (Chemotherapy) 10/2014 - 12/2010
2	Nephrectomy 02/2015 - 01/2013
2	Aftercare (After-Treatment) 12/2010 - 04/2010